Publicaciones Similares
Biosimilars in Mexico
The regulatory body for the approval of
medicines in Mexico is the Federal Commission for Protection Against Health Risks (COFEPRIS)
Why are prices so high in the US?
An In-depth Analysis of High Prices in the U.S. Delve into the statistics, root causes, and strategic interventions shaping the economic landscape in our comprehensive infographic. Uncover the complexities, explore solutions.
Oppotunities for orphan drugs in Latin America
There are ample opportunities for the entry of orphan drugs into the region. The size of the Latin American orphan drug market was USD 14.17 billion in 2021 and it is estimated that it will increase by 7.38% by 2026. Based on the type of drug, the biological sector dominates the orphan drug market for Latin America
Rare Diseases – Orphan drugs- innovative- models of procurement for rare diseases- pricing and reimbursement in Latin America
Orphan drugs used to treat rare diseases have been labeled “orphan drugs” because of their applicability to very small populations, and they respond to public health needs
Biosimilars in Latin America
The regulations for biosimilars vary
considerably from one country to
another, but in general the trend is an
increase in the regulatory standards for their health registration.
Health System in Ecuador
The Ministry of Public Health (MSP) offers health care services to the entire population.